CHRM2
ENSG00000181072
Target class
GPCR
Chromosome
7
Approved drugs
14
Clinical candidates (approved and in development)
20
- Approved drugs
- 14
- Clinical candidates (approved and in development)
- 20
- Chemical probe available
- Yes
- Target name
- CHRM2
- Gene name
- Cholinergic receptor muscarinic 2
- Gene symbol
- CHRM2
- Protein name
- Muscarinic acetylcholine receptor M2
- Gene biotype
- Protein coding
- Gene family
- Cholinergic receptors muscarinic|MicroRNA protein coding host genes
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 8
- Highest tissue expression
- 29.36
- Tissue specificity (Gini)
- 0.867
- Tissue specificity (tau)
- 0.964
- KEGG gene identifiers
- hsa:1129
- Protein interaction confidence
- 0.814538
- Protein interaction partners
- 26
- R-HSA-390648
- R-HSA-418594
- R-HSA-8856825
- R-HSA-8856828
- End position
- 137020255
- Start position
- 136868652
- Chromosome
- 7
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Postsynaptic cell membrane
- Multi-pass membrane protein . Note=Phosphorylation in response to agonist binding promotes receptor internalization. .
- PubMed 22278061
- PubMed 24256733
- PubMed 3443095
- Tissue specificity (tau)
- 0.96371
- Expression inequality (Gini)
- 0.867009
Expression in transcripts per million
- Colon - Sigmoid
- 29.36
- Bladder
- 12.47
- Heart - Atrial Appendage
- 10.81
- Heart - Left Ventricle
- 7.37
- Colon - Transverse
- 7.21
Expression in transcripts per million
- Colon - Sigmoid29.36
- Bladder12.47
- Heart - Atrial Appendage10.81
- Heart - Left Ventricle7.37
- Colon - Transverse7.21
- Esophagus - Gastroesophageal Junction7.15
- Esophagus - Muscularis2.82
- Brain - Hypothalamus1.01
- Lung0.91
- Brain - Frontal Cortex (BA9)0.76
- Testis0.66
- Stomach0.5
- Cervix - Ectocervix0.47
- Brain - Anterior cingulate cortex (BA24)0.44
- Brain - Cortex0.4
- Brain - Caudate (basal ganglia)0.39
- Brain - Putamen (basal ganglia)0.38
- Cervix - Endocervix0.33
- Vagina0.28
- Cells - Cultured fibroblasts0.21
- Brain - Nucleus accumbens (basal ganglia)0.18
- Liver0.17
- Brain - Amygdala0.16
- Brain - Cerebellar Hemisphere0.16
- Brain - Hippocampus0.15
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007187
- GO:0007188
- GO:0007193
- GO:0007197
- GO:0007207
- GO:0007213
- GO:0007399
- GO:0008016
- GO:0009615
- GO:0005886
- GO:0016020
- GO:0030669
- GO:0005515
- GO:0016907
- GO:1990763
decreased pupil diameter
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pupil diameter
- nervous system
- respiratory
- cardiovascular
PubMed 28216264pulmonary hemorrhage
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: pulmonary hemorrhage
- nervous system
- respiratory
- cardiovascular
PubMed 28216264peripheral edema
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: peripheral edema
Biological samples
- cardiovascular system
Evidence sourcevagal effects (key role in control of heart rate and smooth muscle activity)
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: vagal effects (key role in control of heart rate and smooth muscle activity)
Biological samples
- cardiovascular system
Evidence sourcedecreased/increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased heart rate
- nervous system
- respiratory
- cardiovascular
PubMed 28216264bronchospasm
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchospasm
- nervous system
- respiratory
- cardiovascular
PubMed 28216264frothing
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: frothing
- nervous system
- respiratory
- cardiovascular
PubMed 28216264cough
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cough
- nervous system
- respiratory
- cardiovascular
PubMed 28216264decreased PR interval
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased PR interval
- nervous system
- respiratory
- cardiovascular
PubMed 28216264increased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased body temperature
- nervous system
- respiratory
- cardiovascular
PubMed 28216264increased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased heart rate
- nervous system
- respiratory
- cardiovascular
PubMed 28216264palpitations
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: palpitations
Biological samples
- cardiovascular system
Evidence sourceblurred vision
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: blurred vision
- nervous system
- respiratory
- cardiovascular
PubMed 28216264increased/decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased blood pressure
- nervous system
- respiratory
- cardiovascular
PubMed 28216264pulmonary congestion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: pulmonary congestion
- nervous system
- respiratory
- cardiovascular
PubMed 28216264sweating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: sweating
- nervous system
- respiratory
- cardiovascular
PubMed 28216264tachycardia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: tachycardia
Biological samples
- cardiovascular system
Evidence sourceptosis
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: ptosis
- nervous system
- respiratory
- cardiovascular
PubMed 28216264muscle cramps
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: muscle cramps
- nervous system
- respiratory
- cardiovascular
PubMed 28216264bronchoconstriction
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: bronchoconstriction
- nervous system
- respiratory
- cardiovascular
PubMed 28216264bronchorrhea
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchorrhea
- nervous system
- respiratory
- cardiovascular
PubMed 28216264decreased/increased respiratory rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased respiratory rate
- nervous system
- respiratory
- cardiovascular
PubMed 28216264tremors
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: tremors
- nervous system
- respiratory
- cardiovascular
PubMed 28216264exhaustion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: exhaustion
- nervous system
- respiratory
- cardiovascular
PubMed 28216264dysrhythmia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: dysrhythmia
Biological samples
- cardiovascular system
Evidence source
And 5 more, listed on the interactive page.
tachycardia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: tachycardia
Biological samples
- cardiovascular system
PubMed 23197038reflex
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: reflex
Biological samples
- cardiovascular system
PubMed 23197038increased blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased blood pressure
Biological samples
- cardiovascular system
PubMed 23197038tremors
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: tremors
Biological samples
- cardiovascular system
PubMed 23197038negative chronotropy and inotropy
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: negative chronotropy and inotropy
Biological samples
- cardiovascular system
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hM2, is one of one assay component(s) measured or calculated from the NVS_GPCR_hM2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourcebronchoconstriction
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: bronchoconstriction
Biological samples
- cardiovascular system
PubMed 23197038decreased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased heart rate
Biological samples
- cardiovascular system
PubMed 23197038decreased cardiac conduction (PR interval)
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased cardiac conduction (PR interval)
Biological samples
- cardiovascular system
PubMed 23197038decreased cardiac action potential duration
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased cardiac action potential duration
Biological samples
- cardiovascular system
PubMed 23197038
Related records
Trials (583)
- "Death Rattle" - A Double Blind, Randomly Controlled, Crossover Trial
- 0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant
- A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
- A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
- A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients
- A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
- A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
- A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
- A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously
- A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
- A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
- A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
- A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
- A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity
- A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
- A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
- A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
- A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
- A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
Drugs (31)
- Afacifenacin Muscarinic acetylcholine receptor antagonist
- Alcuronium Muscarinic acetylcholine receptor M2 positive allosteric modulator
- ASM-024 Muscarinic acetylcholine receptor M2 antagonist
- Atropine Muscarinic acetylcholine receptor M2 antagonist
- Atropine sulfate Muscarinic acetylcholine receptor M2 antagonist
- Batefenterol Muscarinic acetylcholine receptor M2 antagonist
- Bethanechol Muscarinic acetylcholine receptor M2 agonist
- Bethanechol chloride Muscarinic acetylcholine receptor M2 agonist
- Darifenacin Muscarinic acetylcholine receptor M2 antagonist
- Darifenacin hydrobromide Muscarinic acetylcholine receptor M2 antagonist
- Darotropium Muscarinic acetylcholine receptor antagonist
- Darotropium bromide Muscarinic acetylcholine receptor antagonist
- Fesoterodine Muscarinic acetylcholine receptor M2 antagonist
- Fesoterodine fumarate Muscarinic acetylcholine receptor M2 antagonist
- Glycopyrronium Muscarinic acetylcholine receptor inhibitor
- Glycopyrronium tosylate Muscarinic acetylcholine receptor inhibitor
- Oxybutynin Muscarinic acetylcholine receptor M2 antagonist
- Oxybutynin chloride Muscarinic acetylcholine receptor M2 antagonist
- Propantheline Muscarinic acetylcholine receptor M2 antagonist
- Propantheline bromide Muscarinic acetylcholine receptor M2 antagonist